ARS Pharmaceuticals
SPRY
SPRY
186 hedge funds and large institutions have $1.48B invested in ARS Pharmaceuticals in 2025 Q2 according to their latest regulatory filings, with 26 funds opening new positions, 82 increasing their positions, 47 reducing their positions, and 22 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more funds holding in top 10
Funds holding in top 10: →
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more capital invested
Capital invested by funds: $ → $
18% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 22
8.33% more ownership
Funds ownership: 77.73% → 86.07% (+8.3%)
1% more funds holding
Funds holding: 184 → 186 (+2)
Holders
186
Holding in Top 10
8
Calls
$11.1M
Puts
$4.05M
Top Buyers
| 1 | +$30.2M | |
| 2 | +$29.8M | |
| 3 | +$25.1M | |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
+$22.7M |
| 5 |
Goldman Sachs
New York
|
+$13M |
Top Sellers
| 1 | -$15.3M | |
| 2 | -$13.8M | |
| 3 | -$8.72M | |
| 4 |
RA
Royce & Associates
New York
|
-$6.74M |
| 5 |
NIP
Nicholas Investment Partners
Rancho Santa Fe,
California
|
-$6.22M |
